title: Sample 9
organism: Homo sapiens
description: Protocols: CD14+CD16-HLA-DRhiLin- (CD3, CD4, CD19, CD45RO) monocytes were sorted from frozen PBMC form blood samples from HD (healthy donor), R (responder) and NR (non-responder) at baseline. Representative samples (n=4, each) of responders/non responders/ and healthy donors were selected from archival samples stored in the dermatology biobank according to the same clinical criteria used in the discovery and validation cohorts for CyTOF and FACS analysis. RNA was isolated using the RNA plus micro kit (Qiagen). We used the SMARTer Stranded total rna-seq pico kit (Clontech) for RNA preparations. Libraries for sequencing were generated with the TruSeq RNA Sample Preparation kit (Illumina).
attributes.tag: ENA first public
attributes.value: 2017-12-21
attributes.tag: ENA last update
attributes.value: 2017-12-21
attributes.tag: External Id
attributes.value: SAMEA104446674
attributes.tag: INSDC center alias
attributes.value: UZH
attributes.tag: INSDC center name
attributes.value: University of Zurich
attributes.tag: INSDC first public
attributes.value: 2017-12-21T17:03:29Z
attributes.tag: INSDC last update
attributes.value: 2017-12-21T11:25:49Z
attributes.tag: INSDC status
attributes.value: public
attributes.tag: Submitter Id
attributes.value: E-MTAB-6214:Sample 9
attributes.tag: broker name
attributes.value: ArrayExpress
attributes.tag: cell type
attributes.value: mononuclear cell
attributes.tag: common name
attributes.value: human
attributes.tag: disease
attributes.value: metastatic melanoma
attributes.tag: organism part
attributes.value: blood
attributes.tag: phenotype
attributes.value: CD14+CD16-HLA-DRhiLin-
attributes.tag: response to treatment
attributes.value: non-responder
attributes.tag: sample name
attributes.value: E-MTAB-6214:Sample 9
attributes.tag: treatment
attributes.value: anti-PD-1 immunotherapy